{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-041832","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2024-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.085557+00:00","generated_at":"2026-05-31T01:46:39.300107+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acasti Pharma completes enrollment in pivotal Phase 3 STRIVE-ON trial of GTX-104 for aSAH","bullets":["Patient enrollment completed for GTX-104 (injectable nimodipine) vs oral nimodipine in 100 patients across ~25 U.S. hospitals.","Data readout from STRIVE-ON safety trial expected early calendar 2025; primary endpoint is comparative adverse events including hypotension.","NDA submission to FDA on track for first half of 2025, consistent with timeline.","CEO Prashant Kohli says milestone achieved ahead of original expectations; believes GTX-104 may transform aSAH standard of care."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-041832","json":"https://secwatch.observer/filing/0001140361-24-041832.json","markdown":"https://secwatch.observer/filing/0001140361-24-041832.md","text":"https://secwatch.observer/filing/0001140361-24-041832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036124041832/0001140361-24-041832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036124041832/ef20036277_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:46:39.300107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}